Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer

Phase 1/2 Completed 49 enrolled Bristol-Myers Squibb

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to find the recommended doses of dasatinib and docetaxel given in combination to men with metastatic hormone refractory prostate cancer and to assess the pharmacokinetic interactions between the 2 drugs.

Timeline

Start: 2007-07
Primary completion: 2012-02
Completion: 2013-01

Publications

Araujo JC, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick GE, Trudel GC, Paliwal P, Agrawal S, Logothetis CJ. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer. 2012 Jan 1;118(1):63-71. doi: 10.1002/cncr.26204. Epub 2011 Jul 25.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Docetaxel	Small molecule	60 mg/m2	Other
Comparator	Docetaxel	Small molecule	75 mg/m2	Other
Comparator	dasatinib anhydrous	Small molecule	50 mg	Oral
Comparator	dasatinib anhydrous	Small molecule	70 mg	Oral
Comparator	dasatinib anhydrous	Small molecule	100 mg	Oral
Comparator	dasatinib anhydrous	Small molecule	120 mg	Oral

Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer

Summary

Timeline

Publications

Drugs

Indications